Review Open Access
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Mar 24, 2015; 4(1): 21-26
Published online Mar 24, 2015. doi: 10.5410/wjcu.v4.i1.21
Role of transperineal template biopsy in prostate cancer
Guzanfar Ali Choudry, Mohammed Hidayathullah Khan, Tahir Qayyum, Department of Urology, Dumfries Royal Infirmary, DG1 4AP Dumfries, United Kingdom
Author contributions: Choudry GA and Khan MH were involved in the writing of the manuscript; Qayyum T was involved in the editing of the manuscript and the literature search.
Conflict-of-interest: There is no conflict to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Tahir Qayyum, MBChB, MRCS, PhD, Department of Urology, Dumfries Royal Infirmary, Bankend Road, DG1 4AP Dumfries, United Kingdom. tahir1@doctors.org.uk
Telephone: +44-1387-246246 Fax: +44-1387-246246
Received: May 23, 2014
Peer-review started: May 23, 2014
First decision: July 18, 2014
Revised: January 12, 2015
Accepted: February 4, 2015
Article in press: February 9, 2015
Published online: March 24, 2015

Abstract

Prostate cancer is the most common neoplasm diagnosed in men. Whilst treatment modalities have progressed, diagnostic investigations in terms of biopsy methods have been assessed but there is no consensus of when the different diagnostic methods in terms of transrectal ultrasound (TRUS) or transperineal template (TPT) should be utilised. TPT biopsy has a higher diagnostic yield than TRUS in those with a primary biopsy, in those with previous negative biopsies with TRUS as well as those undergoing saturation biopsies. Despite the increased likelihood of diagnosing cancer with TPT than TRUS this maybe secondary to the increased number of biopsies being utilised. However there is no consensus regarding the ideal number of biopsies that should be utilised with TPT. Furthermore it is felt that the increased number of biopsies utilised with TPT is associated the higher complication rates with TPT. The role of TPT biopsy is recognised in those with previous negative biopsies with transrectal ultrasound but further work is required regarding the ideal number of biopsies. Furthermore, it is felt that TPT biopsy may have a role in primary biopsy.

Key Words: Transrectal prostate biopsy, Transperineal prostate biopsy, Prostate biopsy

Core tip: Transperineal template biopsies are utilised in prostate cancer at an increasing rate instead of transrectal biopsies, yet there is no consensus on how this investigation should be utilised. Here we assess when this method of prostate biopsy is utilised, the number of biopsies that are taken and the method of transperineal template biopsy as well the likelihood of the increase in accuracy in diagnosing prostate cancer.



INTRODUCTION

Prostate cancer is now recognised as a major burden on the global health-care system. In the United States and in Europe, it is the most common neoplasm diagnosed in men and is responsible for 11% of all male cancer deaths[1,2]. After a diagnosis of prostate cancer is made, a number of treatments may be considered depending on the information provided by staging investigations. In patients who are thought to have organ confined prostate cancer, treatment options include radical prostatectomy, external beam radiation therapy, brachytherapy, focal treatment and active monitoring.

The main diagnostic tools utilised for a diagnosis of prostate cancer are digital rectal examination (DRE), serum concentration of Prostate Specific Antigen (PSA) and transrectal ultra sound guided (TRUS) biopsy. Prostate cancer can be detected by DRE alone in patients irrespective of the PSA reading[3]. A suspicious DRE is associated with more aggressive prostate cancer once diagnosed following biopsy[4] with the chance of having malignancy at biopsy higher in those with a suspicious DRE[5].

PSA measurement is now standard practise in prostate cancer diagnosis[6,7] since its first discovery as a serum marker for prostate cancer[8] having been demonstrated to be an independent predictor of cancer in comparison to a suspicious DRE or TRUS[9].

It is felt that performing biopsies under ultrasound guide where a transrectal approach is used for most biopsies is the standard. This is guided by hypoechoic areas in the peripheral zone but this is not always seen as Gray-scale TRUS does not detect areas of malignancy with adequate reliability[10] and as a consequence performing biopsies on only those areas that are hypoechoic would lead to cancers being missed[11] and has led to systematic biopsies being performed[11].

Pathological studies have demonstrated that prostate cancer can be a unifocal and unilateral disease[12] leading to a growing demand for minimally invasive treatment modalities prompting research into focal therapies which allows treatment of the cancer focus and sparing of normal tissue and therefore preserving genitourinary function[13,14]. It is felt that transperineal template (TPT) biopsy has a higher detection rate not of only prostate cancer[15-25] but also of clinically significant prostate cancer[17-19,26-29], anterior cancers[30,31] and has a higher detection rate than TRUS in those with a normal DRE[32]. TPT has a slightly longer training time[33] but has been demonstrated to diagnose cancer in those that have undergone previous negative biopsies via TRUS[26,29,34-39]. TPT biopsies are directed longitudinally to the peripheral zone and anterior part of the prostate so they should detect more cancer than via TRUS[40]. It is felt that this may be due to the inclusion of lateral cores explaining the higher diagnosis rate. It has been demonstrated that TPT biopsies detected significant cancers in those that had undergone TRUS biopsies with earlier negative findings[26,29,34-39] whilst others have demonstrated no difference between TRUS and TPT[41-43].

NUMBER OF BIOPSIES

It is felt that TRUS sextant biopsies are inadequate compared to TPT[15,44] and this results in a significant difference in the detection rates of prostate cancer when compared to twelve biopsies via TRUS or TPT[45-47]. It is felt that sextant biopsies via TPT can be utilised but only in cases of an abnormal DRE or increased PSA otherwise twelve biopsies are required[48]. This also increases the accuracy in Gleason grade in comparison to the final pathology following surgery[49]. It has been suggested that performing twenty two biopsies via TPT may increase the diagnostic accuracy[34] especially for larger sized prostates[50] whilst eight peripheral cores are sufficient for prostate volumes < 30 cc[23]. Furthermore, there is evidence that eighteen biopsies should be utilised in certain situations[51]. It has been demonstrated that using thirty six biopsies via TPT has a better diagnostic yield of prostate cancer then twelve via TRUS in those with normal DRE[25] whilst fourteen biopsies maybe sufficient but there is a risk of missing cancers[52]. Others have suggested that utilising a brachytherapy template with a 5 millimetre grid to guide template biopsies allows the detection of clinically significant prostate cancer[19] and that the volume of the prostate should be utilised as a guide to the number of biopsies with eight cores sufficient for small prostates and more extensive biopsies utilised for larger prostates[23] whereas it is felt that twelve biopsies are sufficient utilising a fan technique[17]. Clearly, larger prostates require higher numbers of biopsies for representative sampling.

Magnetic resonance imaging (MRI) has been demonstrated to have a high degree of accuracy in the detection of clinically significant prostate cancer when compared to radical prostatectomy specimens[53]. This has led to reports that MRI guided TRUS biopsies increase the detection of prostate cancer[54,55] as well as the detection of significant disease[56] with the possibility of utilising less biopsies[57,58]. However, MRI guided biopsy is not a modality that is utilised on a regular basis at the present time.

SATURATION BIOPSIES

In cases where saturation biopsies are utilised for investigation for previous negative biopsies with TRUS, it has been demonstrated that the detection rate can increase between 30%-40% using TRUS saturation biopsies, with the majority of these diagnoses being minimally differentiated disease[59-61]. Furthermore, there is an increase of 38% detection rate by TPT saturation biopsies after previous negative TRUS biopsies suggesting no advantage of TPT saturation biopsies over TRUS saturation biopsies[41,62]. Others have demonstrated that saturation biopsies do increase the detection rate of prostate cancer in those with previous negative biopsies with TRUS but have recommended that saturation biopsies should not be utilised as an initial strategy[63].

PREPARATION

As the TPT approach does not pass through the rectum it should be considered a sterile approach and therefore antibiotics should be recommended for those patients at a high risk of infection. There is little work looking at the role of antibiotics in the setting of TPT and yet many reports of TPT utilise antibiotics on a standard basis[17,23] which can be of concern given the prevalence of antibiotic resistance.

Bowel preparation is common amongst many urologists prior to TPT[64] as is felt that it reduces bacterial load[65] but given that TPT is a sterile procedure, the role of preventing infection may not be appropriate but it is felt that removing faecal material may improve the image of the prostate[66].

COMPLICATIONS

TPT is more invasive, has resource implications[19,67,68] as well as being associated with more complications thought to be as a result of increased number of biopsies being utilised[28,69,70]. There has been no difference in the complication rates following baseline TRUS or TPT[15,23,26,29,41,71-73], even in those that are thought be at increased risk of sepsis undergoing a biopsy via TPT as the primary choice[29] whilst it has been reported that there is a higher rate of urinary retention following saturation biopsies with TPT[62]. This maybe the result that some TPT biopsy cores go through the external urethral sphincter. Where saturation biopsies are to be utilised with TRUS, then the cost implications are similar to TPT as both would require anaesthesia as well as post procedure recovery.

CONCLUSION

Prostate biopsy plays a very important role in the diagnosis of prostate cancer. As prostate cancer is multifocal, it is felt that the detection rate may differ with the number of biopsies and biopsy method.

It has been suggested that TPT biopsies may have a lower rate of sepsis than TRUS and should not be used for only those undergoing a repeat biopsy but in all those in whom a biopsy is indicated[73]. Some authors have demonstrated no difference in detection rates, others have demonstrated a significant difference in the detection of clinically relevant disease and this is the group that it is often difficult in terms of management. Furthermore, this is the group that would benefit the most in terms of appropriate therapy. Those on active surveillance had their disease up-staged following TPT[74] and therefore any additional information in terms of Gleason grade would prove most useful to help plan treatment in this group.

Some issues needs to be addressed in terms of TPT biopsies. There is still not much information regarding the ideal number of biopsies that should be performed using this method and a consensus needs to be agreed upon this number as a significant difference in detection rates has been demonstrated when eighteen biopsies were taken in comparison to six-twelve via TPT[75], suggesting that prostate size should be utilised to decide the ideal number of biopsies[19,23]. The complication rates have been demonstrated to correlate with increased number of biopsies[76] and therefore it is suggested that twelve biopsies are sufficient[17]. Furthermore, despite evidence that TPT biopsies offer a higher diagnostic yield than TRUS, this could be secondary just due to the fact that more biopsies are taken at the time of TPT than TRUS. It is agreed that TPT biopsies are useful in those where previous biopsies have been negative and therefore may aid in the diagnosis in these patients[32,34,39].

Footnotes

P- Reviewer: Gupta A, Kayadibi H, Papatsoris AG S- Editor: Song XX L- Editor: A E- Editor: Lu YJ

References
1.  Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481-488.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 892]  [Cited by in F6Publishing: 954]  [Article Influence: 50.2]  [Reference Citation Analysis (0)]
2.  Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10002]  [Cited by in F6Publishing: 10353]  [Article Influence: 739.5]  [Reference Citation Analysis (0)]
3.  Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42:365-374.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 123]  [Cited by in F6Publishing: 128]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
4.  Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007;70:1117-1120.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 83]  [Cited by in F6Publishing: 91]  [Article Influence: 5.4]  [Reference Citation Analysis (0)]
5.  Gosselaar C, Roobol MJ, Roemeling S, Schröder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol. 2008;54:581-588.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 88]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
6.  Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989;141:1076-1083.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol. 1989;141:1088-1090.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1782]  [Cited by in F6Publishing: 1658]  [Article Influence: 44.8]  [Reference Citation Analysis (0)]
9.  Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542-1547.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 833]  [Cited by in F6Publishing: 861]  [Article Influence: 33.1]  [Reference Citation Analysis (0)]
10.  Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology. 1989;170:609-615.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 150]  [Cited by in F6Publishing: 154]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
11.  Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol. 1994;152:1506-1509.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2011;14:46-52.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 100]  [Cited by in F6Publishing: 86]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]
13.  Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185:1246-1254.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 181]  [Cited by in F6Publishing: 154]  [Article Influence: 11.8]  [Reference Citation Analysis (0)]
14.  Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol. 2007;4:632-642.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 128]  [Cited by in F6Publishing: 134]  [Article Influence: 7.9]  [Reference Citation Analysis (0)]
15.  Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology. 2003;61:961-966.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 88]  [Cited by in F6Publishing: 91]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
16.  Kojima M, Hayakawa T, Saito T, Mitsuya H, Hayase Y. Transperineal 12-core systematic biopsy in the detection of prostate cancer. Int J Urol. 2001;8:301-307.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol. 2001;166:845-850.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 72]  [Cited by in F6Publishing: 47]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
18.  Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience. Urology. 2007;70:27-35.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 155]  [Cited by in F6Publishing: 169]  [Article Influence: 10.6]  [Reference Citation Analysis (0)]
19.  Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013;73:778-787.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 113]  [Cited by in F6Publishing: 105]  [Article Influence: 9.5]  [Reference Citation Analysis (0)]
20.  Zhang FB, Shao Q, Du Y, Tian Y. [Ultrasound-guided transperineal 24-core saturation prostate biopsy is superior to the 14-core scheme in detecting prostate cancer in patients with PSA & lt; 20 microg/L]. Zhonghua Nankexue. 2012;18:306-309.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Takenaka A, Hara R, Hyodo Y, Ishimura T, Sakai Y, Fujioka H, Fujii T, Jo Y, Fujisawa M. Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores. Int J Urol. 2006;13:10-14.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 37]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
22.  Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast TH. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology. 2000;56:617-621.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 65]  [Cited by in F6Publishing: 65]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
23.  Ficarra V, Novella G, Novara G, Galfano A, Pea M, Martignoni G, Artibani W. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol. 2005;48:932-937.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 62]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
24.  Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, Sato T, Nagamori S, Shinohara N, Koyanagi T. Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate. 2004;58:76-81.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 56]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
25.  Nafie S, Mellon JK, Dormer JP, Khan MA. The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng ml(-1.). Prostate Cancer Prostatic Dis. 2014;17:170-173.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 22]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
26.  Klatte T, Swietek N, Schatzl G, Waldert M. Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies. Wien Klin Wochenschr. 2013;125:669-673.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 7]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
27.  Bittner N, Merrick GS, Bennett A, Butler WM, Andreini HJ, Taubenslag W, Adamovich E. Diagnostic Performance of Initial Transperineal Template-guided Mapping Biopsy of the Prostate Gland. Am J Clin Oncol. 2013;Jun 11; Epub ahead of print.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 14]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
28.  Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, Young PR. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology. 2005;65:735-739.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 94]  [Cited by in F6Publishing: 97]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
29.  Vyas L, Acher P, Kinsella J, Challacombe B, Chang RT, Sturch P, Cahill D, Chandra A, Popert R. Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases. BJU Int. 2014;114:32-37.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 69]  [Cited by in F6Publishing: 73]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
30.  Hossack T, Patel MI, Huo A, Brenner P, Yuen C, Spernat D, Mathews J, Haynes AM, Sutherland R, del Prado W. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. J Urol. 2012;188:781-785.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 62]  [Cited by in F6Publishing: 51]  [Article Influence: 4.3]  [Reference Citation Analysis (1)]
31.  Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int. 2012;110:993-997.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 64]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
32.  Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, Butler WM, Adamovich E, Wallner KE. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2010;13:71-77.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 217]  [Cited by in F6Publishing: 201]  [Article Influence: 13.4]  [Reference Citation Analysis (0)]
33.  Shen PF, Zhu YC, Wei WR, Li YZ, Yang J, Li YT, Li DM, Wang J, Zeng H. The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian J Androl. 2012;14:310-315.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 93]  [Cited by in F6Publishing: 91]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
34.  Satoh T, Matsumoto K, Fujita T, Tabata K, Okusa H, Tsuboi T, Arakawa T, Irie A, Egawa S, Baba S. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology. 2005;66:114-118.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 52]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
35.  Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol. 2007;52:715-723.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 106]  [Article Influence: 6.2]  [Reference Citation Analysis (0)]
36.  Bott SR, Henderson A, Halls JE, Montgomery BS, Laing R, Langley SE. Extensive transperineal template biopsies of prostate: modified technique and results. Urology. 2006;68:1037-1041.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 83]  [Cited by in F6Publishing: 87]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
37.  Ekwueme K, Simpson H, Zakhour H, Parr NJ. Transperineal template-guided saturation biopsy using a modified technique: outcome of 270 cases requiring repeat prostate biopsy. BJU Int. 2013;111:E365-E373.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 28]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
38.  Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy. J Urol. 2013;190:509-514.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 49]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
39.  Nafie S, Pal RP, Dormer JP, Khan MA. Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies. World J Urol. 2014;32:971-975.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 7]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
40.  Abdollah F, Novara G, Briganti A, Scattoni V, Raber M, Roscigno M, Suardi N, Gallina A, Artibani W, Ficarra V. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? Urology. 2011;77:921-925.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 63]  [Cited by in F6Publishing: 66]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
41.  Hara R, Jo Y, Fujii T, Kondo N, Yokoyoma T, Miyaji Y, Nagai A. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology. 2008;71:191-195.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 117]  [Cited by in F6Publishing: 115]  [Article Influence: 7.2]  [Reference Citation Analysis (0)]
42.  Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, Fujisawa M. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11:134-138.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 79]  [Cited by in F6Publishing: 83]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
43.  Kawakami S, Yamamoto S, Numao N, Ishikawa Y, Kihara K, Fukui I. Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. Int J Urol. 2007;14:719-724.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 39]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
44.  Demura T, Hioka T, Furuno T, Kaneta T, Gotoda H, Muraoka S, Sato T, Mochizuki T, Nagamori S, Shinohara N. Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. Cancer. 2005;103:1826-1832.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 36]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
45.  Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A, Martini M, Pansadoro V. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol. 2004;171:197-199.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 48]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
46.  Yamamoto S, Kin U, Nakamura K, Hamano M, Nishikawa Y, Takenouchi T, Maruoka M. Transperineal ultrasound-guided 12-core systematic biopsy of the prostate for patients with a prostate-specific antigen level of 2.5-20 ng/ml in Japan. Int J Clin Oncol. 2005;10:117-121.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 18]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
47.  Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605-1612.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 296]  [Cited by in F6Publishing: 288]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
48.  Bigliocchi M, Marini M, Nofroni I, Perugia G, Shahabadi H, Ciccariello M. Prostate cancer detection rate of transrectal ultrasonography, digital rectal examination, and prostate-specific antigen: results of a five-year study of 6- versus 12-core transperineal prostate biopsy. Minerva Urol Nefrol. 2007;59:395-402; 403-406.  [PubMed]  [DOI]  [Cited in This Article: ]
49.  Emiliozzi P, Maymone S, Paterno A, Scarpone P, Amini M, Proietti G, Cordahi M, Pansadoro V. Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol. 2004;172:2224-2226.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 57]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
50.  Huo AS, Hossack T, Symons JL, PeBenito R, Delprado WJ, Brenner P, Stricker PD. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. J Urol. 2012;187:2044-2049.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 37]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
51.  Pepe P, Aragona F. Prostate needle biopsy: 12 vs. 18 cores -- is it necessary? Urol Int. 2005;74:19-22.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 17]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
52.  Takeshita H, Numao N, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Koga F, Saito K, Masuda H, Kawakami S. Diagnostic performance of initial transperineal 14-core prostate biopsy to detect significant cancer. Int Urol Nephrol. 2013;45:645-652.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 6]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
53.  Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, Kamoi K, Villers A. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology. 2009;74:1094-1099.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 189]  [Cited by in F6Publishing: 157]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]
54.  Park BK, Park JW, Park SY, Kim CK, Lee HM, Jeon SS, Seo SI, Jeong BC, Choi HY. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol. 2011;197:W876-W881.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 101]  [Cited by in F6Publishing: 100]  [Article Influence: 7.7]  [Reference Citation Analysis (0)]
55.  Engehausen DG, Engelhard K, Schwab SA, Uder M, Wach S, Wullich B, Krause FS. Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer. ScientificWorldJournal. 2012;2012:975971.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 18]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
56.  Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Fütterer JJ, Barentsz JO. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183:520-527.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 270]  [Cited by in F6Publishing: 291]  [Article Influence: 19.4]  [Reference Citation Analysis (0)]
57.  Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, Freeman A, Allen C, Kirkham A, van der Meulen J. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol. 2013;189:860-866.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 143]  [Cited by in F6Publishing: 158]  [Article Influence: 13.2]  [Reference Citation Analysis (0)]
58.  Chang DT, Challacombe B, Lawrentschuk N. Transperineal biopsy of the prostate--is this the future? Nat Rev Urol. 2013;10:690-702.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 73]  [Cited by in F6Publishing: 77]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
59.  Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol. 2006;50:498-505.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 159]  [Cited by in F6Publishing: 162]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
60.  Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol. 2004;172:94-97.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 107]  [Cited by in F6Publishing: 110]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
61.  Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166:86-91; discussion 91-92.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 302]  [Cited by in F6Publishing: 186]  [Article Influence: 8.1]  [Reference Citation Analysis (0)]
62.  Moran BJ, Braccioforte MH. Stereotactic transperineal prostate biopsy. Urology. 2009;73:386-388.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 21]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
63.  Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi-Galluzzi C, Jones JS. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. J Urol. 2008;179:1746-1750; discussion 1750.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 59]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
64.  Davis M, Sofer M, Kim SS, Soloway MS. The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J Urol. 2002;167:566-570.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 19]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
65.  Jeon SS, Woo SH, Hyun JH, Choi HY, Chai SE. Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy. Urology. 2003;62:461-466.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 79]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
66.  Prayer-Galetti T, Ficarra V, Franceschini R, Liguori G, Martino P, Schiavina R. [When to carry out prostate biopsy]. Arch Ital Urol Androl. 2005;77:3-16.  [PubMed]  [DOI]  [Cited in This Article: ]
67.  Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014;66:732-751.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 244]  [Cited by in F6Publishing: 213]  [Article Influence: 19.4]  [Reference Citation Analysis (0)]
68.  de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, Frauscher F, Greene D, Harisinghani M, Haustermans K. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24:775-780.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 145]  [Cited by in F6Publishing: 153]  [Article Influence: 10.9]  [Reference Citation Analysis (0)]
69.  Buskirk SJ, Pinkstaff DM, Petrou SP, Wehle MJ, Broderick GA, Young PR, Weigand SD, O’Brien PC, Igel TC. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Radiat Oncol Biol Phys. 2004;59:1360-1366.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 40]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
70.  Merrick GS, Taubenslag W, Andreini H, Brammer S, Butler WM, Adamovich E, Allen Z, Anderson R, Wallner KE. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int. 2008;101:1524-1529.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 81]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
71.  Li H, Yan W, Zhou Y, Ji Z, Chen J. Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases. Urology. 2007;70:1157-1161.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 34]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
72.  Miller J, Perumalla C, Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg. 2005;75:48-50.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 58]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
73.  Grummet JP, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon DA, O’Reilly M, Murphy D. Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int. 2014;114:384-388.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 71]  [Article Influence: 7.1]  [Reference Citation Analysis (0)]
74.  Taira AV, Merrick GS, Bennett A, Andreini H, Taubenslag W, Galbreath RW, Butler WM, Bittner N, Adamovich E. Transperineal template-guided mapping biopsy as a staging procedure to select patients best suited for active surveillance. Am J Clin Oncol. 2013;36:116-120.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 38]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
75.  Pepe P, Aragona F. Prostate biopsy: results and advantages of the transperineal approach--twenty-year experience of a single center. World J Urol. 2014;32:373-377.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 27]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
76.  Pepe P, Aragona F. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology. 2013;81:1142-1146.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 91]  [Cited by in F6Publishing: 99]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]